News
Stay up to date on the progress of Vesigen’s breakthrough technology
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
Vesigen Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
CAMBRIDGE, Mass., May 2, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Vesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic Strategy
CAMBRIDGE, Mass., March 14, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing targeted therapies by engineering a ...
Vesigen Therapeutics, Inc. Announces Expansion of Scientific Advisory Board
CAMBRIDGE, Mass., February 7, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally ...
Vesigen Therapeutics Names Rakhshita Dhar to Board of Directors
CAMBRIDGE, Mass., January 30, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally ...
Vesigen Therapeutics Appoints Paulash Mohsen as Chief Executive Officer
CAMBRIDGE, Mass., Apr. 11, 2022 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery ...
Vesigen Therapeutics Presents at 3rd Exosome-Based Therapeutic Development Summit: Expanding the Therapeutic Boundaries of Exosomes
CAMBRIDGE, Mass., Nov. 16, 2021 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle non-viral ...
